Wells Fargo
ZNTL icon

Wells Fargo’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Wells Fargo’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-600
Closed -$17K – 7500
2022
Q2 		$17K Buy
+600
New +$15.9K ﹤0.01% 5538

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wells Fargo's ZNTL Position: Q1 2026 in Review

Wells Fargo opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #7155 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ZNTL as recently as Q2 2025.

Wells Fargo first reported a position in ZNTL in Q2 2020 and has held it in 22 quarters since. The position peaked at $33M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Wells Fargo held 1 share of Zentalis Pharmaceuticals worth $1 as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Wells Fargo position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #7155 holding.
  • Wells Fargo first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Wells Fargo's Zentalis Pharmaceuticals position peaked at $33M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.